1. Variability in P-glycoprotein inhibitory potency (IC(5)(0)) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria;Bentz;Drug Metabol. Disposition: Biol. Fate Chem.,2013
2. Phosphatidylethanolamine is a key regulator of membrane fluidity in eukaryotic cells;Dawaliby;J. Biol. Chem.,2016
3. EMA, 2012. Guideline on the investigation of drug interactions. https://www.ema.europa.eu/documents/scientific-guideline/guideline-investigation-drug-interactions_en.pdf.
4. FDA, 2017. In Vitro Metabolism and Transporter Mediated Drug-Drug Interaction Studies Guidance for Industry. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM581965.pdf.
5. FDA, 2020. In vitro drug interaction studies — cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. https://www.fda.gov/media/134582/download.